Precision BioSciences Inc PBCAR0191 Clinical Data Call Transcript
Good day, and thank you for standing by. Welcome to the Precision Biosciences CD19 Update Conference Call. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Alex Kelly, Chief Financial Officer. Please go ahead.
All right. Thank you, Victor, and good morning, everyone, and welcome to our webcast to discuss the promising progress that we've made on 2 strategies, to optimize the durability of allogeneic CAR T therapy in non-Hodgkin lymphoma.
Before we begin, I would like to remind you that some of the statements that we make on this webcast may be considered forward-looking statements. Our forward-looking statements are within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risk factors in Precision's annual report Form 10-K and our first quarter 2021 10-Q.
All forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |